Evaluation of Rabies Biologics Against Irkut Virus Isolated in China

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2013 Aug 16

PMID 23946522

Citations 10

Authors

Ye Liu

Qi Chen

Fei Zhang

Shoufeng Zhang

Nan Li

Hai Lian

Ying Wang

Jinxia Zhang

Rongliang Hu

Affiliations

Soon will be listed here.

Abstract

An Irkut virus (IRKV) was recently isolated from a bat in China. The protective ability of rabies biologics available in the Chinese market and experimental biologics against the rabies virus (RABV) and IRKV were assessed in a hamster model via preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) experiments. The results demonstrated that a single dose of rabies vaccine did not induce adequate protection against IRKV infection. However, routine PrEP with three doses of vaccine induced complete protection against IRKV infection. Higher doses of RABV immunoglobulins and alpha interferon were required during PEP to protect hamsters against IRKV versus RABV infection. Experimental recombinant vaccines containing IRKV glycoproteins induced more-reliable protection against IRKV than against RABV infection. Those findings may be explained by limited cross-neutralization of these viruses (confirmed via in vitro tests) in conjunction with antigenic distances between RABV and IRKV. These results indicate that the development and evaluation of new biologics for PrEP and PEP are required to ensure sufficient protection against IRKV infection in China and other territories where this virus is present.

Citing Articles

Toward the Development of a Pan-Lyssavirus Vaccine.

Ben Hamed S, Myers J, Chandwani A, Wirblich C, Kurup D, Paran N Viruses. 2024; 16(7).

PMID: 39066269 PMC: 11281706. DOI: 10.3390/v16071107.

Comparative pathogenesis of different phylogroup I bat lyssaviruses in a standardized mouse model.

Klein A, Eggerbauer E, Potratz M, Zaeck L, Calvelage S, Finke S PLoS Negl Trop Dis. 2022; 16(1):e0009845.

PMID: 35041652 PMC: 8797209. DOI: 10.1371/journal.pntd.0009845.

Epidemiology of Animal Rabies - China, 2010-2020.

Feng Y, Ma J, Sun S, Chi L, Kou Z, Tu C China CDC Wkly. 2021; 3(39):815-818.

PMID: 34594998 PMC: 8477053. DOI: 10.46234/ccdcw2021.202.

Renewed Public Health Threat from Emerging Lyssaviruses.

Fooks A, Shipley R, Markotter W, Tordo N, Freuling C, Muller T Viruses. 2021; 13(9).

PMID: 34578350 PMC: 8472001. DOI: 10.3390/v13091769.

Neglected challenges in the control of animal rabies in China.

Miao F, Li N, Yang J, Chen T, Liu Y, Zhang S One Health. 2021; 12:100212.

PMID: 33553562 PMC: 7843516. DOI: 10.1016/j.onehlt.2021.100212.

References

Sloan S, Hanlon C, Weldon W, Niezgoda M, Blanton J, Self J . Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine. 2007; 25(15):2800-10. DOI: 10.1016/j.vaccine.2006.12.031. View

Badrane H, Bahloul C, Perrin P, Tordo N . Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J Virol. 2001; 75(7):3268-76. PMC: 114120. DOI: 10.1128/JVI.75.7.3268-3276.2001. View

Hilfenhaus J, Weinmann E, Majer M, Barth R, Jaeger O . Administration of human interferon to rabies virus-infected monkeys after exposure. J Infect Dis. 1977; 135(5):846-9. View

Liu Y, Zhang S, Zhao J, Zhang F, Hu R . Isolation of Irkut virus from a Murina leucogaster bat in China. PLoS Negl Trop Dis. 2013; 7(3):e2097. PMC: 3591329. DOI: 10.1371/journal.pntd.0002097. View

Vos A, Neubert A, Pommerening E, Muller T, Dohner L, Neubert L . Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration. J Gen Virol. 2001; 82(Pt 9):2191-2197. DOI: 10.1099/0022-1317-82-9-2191. View

Jallet C, Jacob Y, Bahloul C, Drings A, Desmezieres E, Tordo N . Chimeric lyssavirus glycoproteins with increased immunological potential. J Virol. 1998; 73(1):225-33. PMC: 103826. DOI: 10.1128/JVI.73.1.225-233.1999. View

Hanlon C, Kuzmin I, Blanton J, Weldon W, Manangan J, Rupprecht C . Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Res. 2005; 111(1):44-54. DOI: 10.1016/j.virusres.2005.03.009. View

Marston D, Horton D, Ngeleja C, Hampson K, McElhinney L, Banyard A . Ikoma lyssavirus, highly divergent novel lyssavirus in an African civet. Emerg Infect Dis. 2012; 18(4):664-7. PMC: 3309678. DOI: 10.3201/eid1804.111553. View

Anderson R, Haskell R, Xia H, Roessler B, Davidson B . A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther. 2000; 7(12):1034-8. DOI: 10.1038/sj.gt.3301197. View

10.

Wang Y, Rowley K, Booth B, Sloan S, Ambrosino D, Babcock G . G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates. Antiviral Res. 2011; 91(2):187-94. DOI: 10.1016/j.antiviral.2011.06.002. View

11.

Ceballos N, Vazquez Moron S, Berciano J, Nicolas O, Lopez C, Juste J . Novel lyssavirus in bat, Spain. Emerg Infect Dis. 2013; 19(5):793-5. PMC: 3647500. DOI: 10.3201/eid1905.121071. View

12.

Benmansour A, Leblois H, Coulon P, Tuffereau C, Gaudin Y, Flamand A . Antigenicity of rabies virus glycoprotein. J Virol. 1991; 65(8):4198-203. PMC: 248855. DOI: 10.1128/JVI.65.8.4198-4203.1991. View

13.

Hu R, Tang Q, Tang J, Fooks A . Rabies in China: an update. Vector Borne Zoonotic Dis. 2008; 9(1):1-12. DOI: 10.1089/vbz.2008.0046. View

14.

Marissen W, Kramer R, Rice A, Weldon W, Niezgoda M, Faber M . Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J Virol. 2005; 79(8):4672-8. PMC: 1069557. DOI: 10.1128/JVI.79.8.4672-4678.2005. View

15.

Wilde H, Sirikawin S, Sabcharoen A, Kingnate D, Tantawichien T, Harischandra P . Failure of postexposure treatment of rabies in children. Clin Infect Dis. 1996; 22(2):228-32. DOI: 10.1093/clinids/22.2.228. View

16.

Cliquet F, Aubert M, Sagne L . Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J Immunol Methods. 1998; 212(1):79-87. DOI: 10.1016/s0022-1759(97)00212-3. View

17.

Houimel M, Dellagi K . Peptide mimotopes of rabies virus glycoprotein with immunogenic activity. Vaccine. 2009; 27(34):4648-55. DOI: 10.1016/j.vaccine.2009.05.055. View

18.

Bahloul C, Jacob Y, Tordo N, Perrin P . DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses. Vaccine. 1998; 16(4):417-25. DOI: 10.1016/s0264-410x(97)00204-1. View

19.

Muller T, Dietzschold B, Ertl H, Fooks A, Freuling C, Fehlner-Gardiner C . Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis. 2009; 3(11):e542. PMC: 2765635. DOI: 10.1371/journal.pntd.0000542. View

20.

Bakker A, Marissen W, Kramer R, Rice A, Weldon W, Niezgoda M . Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol. 2005; 79(14):9062-8. PMC: 1168753. DOI: 10.1128/JVI.79.14.9062-9068.2005. View